Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023

BUY
$14.2 - $18.63 $208,314 - $273,302
14,670 New
14,670 $233,000
Q2 2022

Aug 12, 2022

SELL
$13.01 - $27.22 $307,179 - $642,691
-23,611 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$20.94 - $27.5 $494,414 - $649,302
23,611 New
23,611 $572,000
Q3 2021

Nov 02, 2021

SELL
$15.78 - $24.77 $177,272 - $278,266
-11,234 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$19.4 - $27.42 $19,438 - $27,474
1,002 Added 9.79%
11,234 $274,000
Q1 2021

May 14, 2021

SELL
$25.02 - $54.99 $138,435 - $304,259
-5,533 Reduced 35.1%
10,232 $264,000
Q4 2020

Feb 12, 2021

BUY
$41.04 - $56.79 $375,351 - $519,401
9,146 Added 138.18%
15,765 $843,000
Q3 2020

Nov 04, 2020

BUY
$36.42 - $57.0 $2,840 - $4,446
78 Added 1.19%
6,619 $273,000
Q2 2020

Jul 17, 2020

SELL
$39.26 - $52.73 $65,053 - $87,373
-1,657 Reduced 20.21%
6,541 $317,000
Q1 2020

Apr 21, 2020

SELL
$31.65 - $46.87 $123,213 - $182,464
-3,893 Reduced 32.2%
8,198 $346,000
Q4 2019

Feb 12, 2020

BUY
$36.21 - $51.4 $114,061 - $161,910
3,150 Added 35.23%
12,091 $517,000
Q3 2019

Nov 07, 2019

BUY
$22.22 - $44.01 $198,669 - $393,493
8,941 New
8,941 $322,000
Q3 2018

Nov 14, 2018

SELL
$13.03 - $21.81 $513,017 - $858,703
-39,372 Closed
0 $0
Q2 2018

Jul 30, 2018

SELL
$15.07 - $22.34 $7,474 - $11,080
-496 Reduced 1.24%
39,372 $601,000
Q1 2018

Apr 16, 2018

SELL
$22.47 - $32.33 $238,631 - $343,344
-10,620 Reduced 21.03%
39,868 $896,000
Q4 2017

Feb 09, 2018

BUY
$26.84 - $39.14 $60,551 - $88,299
2,256 Added 4.68%
50,488 $1.52 Million
Q3 2017

Oct 26, 2017

BUY
$29.49 - $38.37 $68,564 - $89,210
2,325 Added 5.06%
48,232 $1.82 Million
Q2 2017

Aug 15, 2017

BUY
N/A
45,907
45,907 $1.28 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.